Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2014

View Archived Issues

Agios Pharmaceuticals begins phase I study of AG-120 in advanced solid tumors

Fusion peptide inhibitor of TFPI designed for treatment of hemophilia

New clinical data on sebelipase alfa for LAL deficiency presented

Preclinical data support further testing of intravenous SBC-103 for MPS-III B

Preterm labor associated with genetic variants linked to pre-eclampsia

VentiRx Pharmaceuticals presents data on VTX-2337 plus cetuximab in SCCHN

Grant awarded to BerGenBio for therapeutics for drug-resistant cancers

Seattle BioMed awarded NIH grant to develop vaccine against HIV

FDA accepts intravenous carbamazepine NDA for review

AbbVie researchers prepare and test PDE10A inhibitors for CNS disorders

U.S. researchers report development of arsenoplatin anticancer agents

Trophos reports topline data for olesoxime in spinal muscular atrophy

Janssen Pharmaceutica divulges N-type calcium channel blockers for pain

FDA grants fast track designation to REG-1

Addition of dupilumab leads to improvements in clinical efficacy in patients with atopic dermatitis

Omeros reports ex vivo data on OMS-721 for aHUS

RedHill Biopharma provides update on RHB-102 development

Northwest Biotherapeutics obtains German approvals for DCVax-L programs

Merck & Co. patents detail novel AMPK activators for diabetes

Redx Pharma and Pierre Fabre establish onco-dermatology collaboration

MediciNova announces start of MN-166 clinical study for marijuana dependence

Phase III study of Nexavar adjuvant treatment in HCC fails to meet primary endpoint

New grant supports partnership between EMD Millipore and Promethera Biosciences

Kythera acquires ex-U.S. and Canadian rights to ATX-101 from Bayer

Wright Medical reaches agreement on PMA amendment for Augment Bone Graft

Topline results released from phase II study of GCS-100 for chronic kidney disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...